Abstract: Systems and methods for diagnosing and/or treating diseases as well as monitoring disease treatment. For diagnosis, the present invention uses nanoparticle-based assemblies, which comprise a nanoparticle; a surrogate marker; and a means for detecting a specific chemical entity. In certain embodiments, nanoparticle-based assemblies include a payload for simultaneous diagnosis and treatment of disease. In further embodiments, a therapeutic drug and therapeutic drug marker are administered to a patient to monitor disease treatment. Bodily fluid samples are analyzed using sensor technology to detect the presence of surrogate and/or therapeutic drug markers to provide an efficient and accurate means for diagnosing a disease and/or monitoring disease treatment.

Abstract: The invention provides novel closed-loop neuroprosthetic devices and systems for preventing seizures in which control of the delivery of therapeutic electrical stimulation to a neural structure being monitored is determined by the dynamical electrophysiological state of the neural structure. In certain embodiments, a controller which generates predetermined control input is activated based on an Automated Seizure Warning system. Other embodiments of the systems and methods encompass direct control systems wherein the controller design is based on chaos theory. Yet other versions embody model-based control systems in which controller design is based on a model that represents the relationship between the control input and the dynamical descriptor.

Abstract: Techniques for investigating dynamical behavior of complex systems for monitoring, diagnosing, and predicting future behavior and trends are presented. A method includes generating a multi-dimensional representation for each signal acquired from corresponding channels of a multi-dimensional system, and generating dynamical profiles for each channel in accordance with one of multiple dynamical metrics. The method includes calculating multiple first statistical measures for a group of the channels that reflect a level of interaction among the channel group associated with at least one of the metrics. The method includes calculating in an initialization period a second statistical measure for each of the first statistical measures that reflect the association of the first statistical measures with related occurrences under investigation.

Abstract: The present invention includes systems and methods for monitoring therapeutic drug concentration in blood by detecting markers, such as odors, upon exhalation by a patient after the drug is taken, wherein such markers result either directly from the drug itself or from an additive combined with the drug. In the case of olfactory markers, the invention preferably utilizes electronic sensor technology, such as the commercial devices referred to as “artificial” or “electronic” noses or tongues, to non-invasively monitor drug levels in blood. The invention further includes a reporting system capable of tracking drug concentrations in blood (remote or proximate locations) and providing the necessary alerts with regarding to ineffective or toxic drug dosages in a patient.